With immediate effect, Dr. Jürgen O. Böhm will take on the role of corporate management at Hemovent GmbH. As the new Chief Executive Officer and Chief Medical Officer, he will support for the two previous Managing Directors and Founders Christof Lenz (CFO) and Dr. Oliver Marseille (CTO). The medical technology company with around 35 employees is thus gaining an experienced expert to expand its corporate development. Hemovent is prepared for the next growth phase thanks to this strategic addition to its management team.
“We are very glad that we were able to recruit Jürgen Böhm for Hemovent. His many years of experience using ECLS products and his expertise in corporate management and sales will help us to achieve our goals even more efficiently – of that I am sure,” said Christof Lenz, who is taking on a new role as CFO, effective immediately.
Dr. Böhm specialized in heart surgery and has over 12 years of clinical experience. He started his career in medical device industry as the Clinical Director at Maquet Cardiopulmonary AG. For the last 10 years he was a member of the Xenios AG Executive Board, where he was responsible for Clinical Affairs and Operations. He also drove and supported corporate development and realized innovative solutions for the treatment of heart and lung failure.
“I am very much looking forward to the new challenge of working at Hemovent. Christof Lenz and Oliver Marseille created an extremely innovative product, laying the foundation for entering the market and further sales growth. Now the successful market launch of the MOBYBOX™ System and consistent further development of our business are the highest priorities,” said Dr. Böhm.
“We are very glad that we were able to recruit Jürgen Böhm for Hemovent. His many years of experience using ECLS products and his expertise in corporate management and sales will help us to achieve our goals even more efficiently – of that I am sure,” said Christof Lenz, who is taking on a new role as CFO, effective immediately.
Dr. Böhm specialized in heart surgery and has over 12 years of clinical experience. He started his career in medical device industry as the Clinical Director at Maquet Cardiopulmonary AG. For the last 10 years he was a member of the Xenios AG Executive Board, where he was responsible for Clinical Affairs and Operations. He also drove and supported corporate development and realized innovative solutions for the treatment of heart and lung failure.
“I am very much looking forward to the new challenge of working at Hemovent. Christof Lenz and Oliver Marseille created an extremely innovative product, laying the foundation for entering the market and further sales growth. Now the successful market launch of the MOBYBOX™ System and consistent further development of our business are the highest priorities,” said Dr. Böhm.
